Lawmakers are pushing for new legislation aimed at cutting prescription drug expenses by streamlining the approval process for biosimilar medications. The proposed Biosimilar Red Tape Elimination Act targets the current interchangeability requirement, which critics argue adds unnecessary delays and costs to bringing lower-cost alternatives to market. Supporters claim the change could make life-saving treatments more accessible without compromising safety standards. The debate centers on balancing regulatory efficiency with patient protection in the biologics market.
Congress is being urged to pass the Biosimilar Red Tape Elimination Act to reduce medication costs by removing the costly interchangeability standard for biologics.
